Women are missing from PrEP messaging
When most respondents in a population don’t know about a particular medication, that means that the word is not getting out. Although efforts may have gotten better since 2013, the reality is that most women still are not considered in the marketing of PrEP especially among people that have some high-risk activities within their lifestyle.
The parallels of this lack of knowledge continue a legacy of female bias when it comes to sexual health topics. The female condom is one example of a tool that was meant to empower women to protect themselves. However, the commitment by the health community to engrain it in our cultural sexual education failed and it is always seen as an option that men and women don’t fully embrace.
Find out more on HIVnet.com.
From NBC online…
Black women continue to be diagnosed with HIV at disproportionately high rates relative to white and Hispanic/Latina women, according to a report released Thursday by the Centers for Disease Control and Prevention.
Despite recent progress that has seen new HIV diagnoses decrease by 21 percent from 2010 to 2016, black women still accounted for 6 in 10 new HIV infections among women in 2016.
…Prep is one way for black women to protect themselves from the virus.
“When we look at the use of Prep, we find that there are disproportionate uses of the drugs. We find that communities of color use Prep less than other communities. Some are not even aware that Prep is out there,” Angarone said.
…Cost also plays a crucial role in black women seeking treatment. Public health experts believe that making Prep and HIV-treatment medications, such as Truvada, affordable to all populations is vital.
“Cost plays a significant role in women seeking treatment. They want to know that insurance covers it. Insurance coverage for Prep is also important,” Angarone said.
“Ultimately, the health of black women has to be made a priority,” Angarone said.
“We have to ask ourselves as a community, how do we get all of the testing strategies that have been working for other populations in place to bring about similar outcomes to the African American female community?”
Read the full article.
From NBC News…
In a major shift, pharmaceutical giant Gilead Sciences will begin airing television ads for PrEP, its HIV prevention medication. The company said the ads, which will start in June and run through August, are “designed to encourage candid conversations around sexual health and promote public awareness of HIV prevention.”
PrEP, or pre-exposure prophylaxis, involves taking a daily pill to prevent HIV transmission. Major clinical trials have shown that PrEP — also known by its brand name, Truvada — is safe and effective at preventing HIV if taken daily. The pill is also recommended by the Centers for Disease Control and Prevention for at-risk groups.
Since the Food and Drug Administration (FDA) approved Truvada for HIV prevention in 2012, Gilead has leaned on public health agencies to promote the drug. New York City has for years placed advertisements on subways and buses to promote PrEP, and the District of Columbia’s health department aired its own racy HIV PrEP television ad earlier this year.
Read the full article.
From the CDC…
Protect yourself, learn about PrEP (Pre-Exposure Prophylaxis), how it works, how to get it, and if it’s the right choice for you.
Find out more on the Centers for Disease Control and Prevention Website.